ライフサイエンスコーパス: sleep apnoea

1 ced respiratory chemosensitivity and central sleep apnoea.

2 ion is impaired in patients with obstructive sleep apnoea.

3 ng hypertension in patients with obstructive sleep apnoea.

4 jor clinical problem of cyclical obstructive sleep apnoea.

5 echanism linking hypertension to obstructive sleep apnoea.

6 ascular disease in patients with obstructive sleep apnoea.

7 es, baseline blood pressure, and severity of sleep apnoea.

8 s widely used as a treatment for obstructive sleep apnoea.

9 p with cardiopulmonary instability caused by sleep apnoea.

10 rders coupled with an increased incidence of sleep apnoea.

11 ases such as hypertension, heart failure and sleep apnoea.

12 treatment for patients with mild obstructive sleep apnoea.

13 logical conditions, particularly obstructive sleep apnoea.

14 ociated with sleep disruption in obstructive sleep apnoea.

15 y pressure in patients with mild obstructive sleep apnoea.

16 ty of life in patients with mild obstructive sleep apnoea.

17 threshold, in participants with obstructive sleep apnoea.

18 positive airway pressure-treated obstructive sleep apnoea.

19 stimate the global prevalence of obstructive sleep apnoea.

20 m for elevated blood pressure in obstructive sleep apnoea.

21 al neurostimulation in patients with central sleep apnoea.

22 a promising therapeutic approach for central sleep apnoea.

23 LVEF </=45%) treated for predominant central sleep apnoea.

24 arely developed specifically for obstructive sleep apnoea.

25 M, hypertension, angina, MI, and obstructive sleep apnoea.

26 or abnormal sleep behaviours and obstructive sleep apnoea.

27 c syndrome, type 2 diabetes, and obstructive sleep apnoea.

28 r airway motor disorders such as obstructive sleep apnoea.

29 infant death syndrome (SIDS) and obstructive sleep apnoea.

30 MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).

31 M1, ANKRD12 and ZBTB21), snoring (WDR59) and sleep apnoea (13 genes).

32 intermittent hypoxia (CIH) is a hallmark of sleep apnoea, a condition associated with diverse clinic

33 data on the global prevalence of obstructive sleep apnoea, a disorder associated with major neurocogn

34 Obstructive sleep apnoea, a syndrome that leads to recurrent intermi

35 Prevalence estimates for obstructive sleep apnoea across studies using different diagnostic c

36 The assessment of how obstructive sleep apnoea affects cognition depends on the specificit

37 012 scoring criteria to identify obstructive sleep apnoea, allowing determination of an equivalent ap

38 cal disorders, including cerebral ischaemia, sleep apnoea, Alzheimer's disease, multiple sclerosis, a

39 se of getting up in the morning, snoring and sleep apnoea) among 450,000 participants from UK Biobank

40 Thirteen participants with sleep apnoea and 13 controls completed two trials.

41 n and women) have mild to severe obstructive sleep apnoea and 425 million (399-450) adults aged 30-69

42 of negative genetic testing were obstructive sleep apnoea and a normal 12-lead ECG (both P < .04).

43 ctive pulmonary disease, asthma, obstructive sleep apnoea and acute lung injury.

44 currently in clinical trials for obstructive sleep apnoea and atrial fibrillation(16).

45 ia as a consequence of increased obstructive sleep apnoea and cardiovascular disease.

46 ittent hypoxia (CIH) occurs in patients with sleep apnoea and has adverse effects on multiple physiol

47 st, e.g. essential hypertension, obstructive sleep apnoea and heart failure.

48 sis and gynaecomastia, worsening obstructive sleep apnoea and increasing cardiovascular morbidity and

49 bsence of RTN neurons probably underlies the sleep apnoea and lack of chemoreflex that characterize c

50 ion, but the association between obstructive sleep apnoea and myocardial infarction, stroke, and cong

51 specific physiological sleep disorders--eg, sleep apnoea and periodic limb movement disorder--are es

52 focus on the association between obstructive sleep apnoea and stroke reviewing both the epidemiologic

53 exity of the association between obstructive sleep apnoea and the brain.

54 Obstructive sleep apnoea and type 2 diabetes are common medical diso

55 arction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of h

56 erapy should be screened for the presence of sleep apnoea, and if present, administration of intermit

57 tension, chronic kidney disease, obstructive sleep apnoea, and metabolic disease including diabetes a

58 Coronary Syndrome and Nonsleepy Obstructive Sleep Apnoea, and Sleep Apnoea Cardiovascular Endpoints

59 ity may be impaired in some individuals with sleep apnoea, and that exogenously activating pathways g

60 cal phenotypes including ptosis, obstructive sleep apnoea, and the occurrence of seizures.

61 troke survivors with obstructive and central sleep apnoea, and the temporal evolution of sleep apnoea

62 leep-related disorders including obstructive sleep apnoea (apnea), REM sleep behaviour disorder (RBD)

63 Male participants with obstructive sleep apnoea (apnoea-hypopnoea index > 5 events/h), matc

64 8 years to <=80 years) with mild obstructive sleep apnoea (apnoea-hypopnoea index [AHI] >=5 to <=15 e

65 CIH and sleep apnoea are characterized by increased reactive oxy

66 Many forms of sleep apnoea are characterized by recurrent reductions i

67 eep movements and behaviours and obstructive sleep apnoea, as confirmed by polysomnography.

68 ddress these shortcomings, the management of sleep apnoea associated with stroke should be integrated

69 Moreover, the pathophysiology of sleep apnoea associated with stroke, the proportion of s

70 Novel markers of sleep apnoea-associated hypoxic burden and cardiac auton

71 rimary outcome was prevalence of obstructive sleep apnoea based on AASM 2012 diagnostic criteria in i

72 dies reporting the prevalence of obstructive sleep apnoea based on objective testing methods.

73 e acute phase after stroke, with obstructive sleep apnoea being the most common subtype.

74 Obstructive sleep apnoea can be diagnosed on the basis of characteri

75 and Nonsleepy Obstructive Sleep Apnoea, and Sleep Apnoea Cardiovascular Endpoints Study randomized t

76 Obstructive sleep apnoea causes sleepiness, road traffic accidents,

77 ronic intermittent hypoxia (CIH, a model for sleep apnoea) causes sympathetic overactivity, cardiovas

78 insufficiency in diverse conditions, such as sleep apnoea, cervical spinal injury or amyotrophic late

79 common sleep disorders, such as obstructive sleep apnoea, chronic insomnia, and circadian rhythm dis

80 l trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group on subtherape

81 ause brain hypoperfusion such as obstructive sleep apnoea, congestive heart failure, cardiac arrhythm

82 capnic hypoxia characteristic of obstructive sleep apnoea could promote hypertension by increasing sN

83 p-deprived normal subjects and patients with sleep apnoea could react differently.

84 olic abnormalities in those with obstructive sleep apnoea could reduce cardiovascular disease risk an

85 will be discussed, management of obstructive sleep apnoea could soon transition from a so-called one

86 Men with obstructive sleep apnoea, defined as an Epworth sleepiness score of

87 population of patients with mild obstructive sleep apnoea diagnosed using the American Academy of Sle

88 Dips suggestive of obstructive sleep apnoea did not predict CNS events, and adenotonsil

89 e than half of stroke survivors present with sleep apnoea during the acute phase after stroke, with o

90 by reduced inspiratory motor output, such as sleep apnoea, endogenous mechanisms of compensatory plas

91 n blood pressure in 118 men with obstructive sleep apnoea (Epworth score > 9, and a > 4% oxygen desat

92 Patients with obstructive sleep apnoea experience chronic intermittent hypoxia-hyp

93 Following a stroke, sleep apnoea frequency and severity might decrease over

94 69 years have moderate to severe obstructive sleep apnoea globally.

95 r related pathologies, including obstructive sleep apnoea, heart failure and diabetes.

96 Obstructive sleep apnoea-hypopnoea syndrome (OSAHS) (HR=1.841, 95% C

97 Obstructive sleep apnoea/hypopnoea syndrome, depression and anxiety

98 in 24.5% (13/53); five of these patients had sleep apnoea/hypopnoea syndrome, six had depression and

99 ater improvements in severity of obstructive sleep apnoea (i.e. reduction in event frequency by 83%,

100 tivity observed in patients with obstructive sleep apnoea (i.e. reflex compensation for an anatomical

101 e in Coronary Artery Disease and Obstructive Sleep Apnoea, Impact of Continuous Positive Airway Press

102 cause of perinatal mortality in infants and sleep apnoea in adults, but the mechanisms of respirator

103 pearance of OSA and the emergence of central sleep apnoea in conditions such as high altitude.

104 Early identification of obstructive sleep apnoea in patients with metabolic dysfunction, inc

105 red respiratory chemosensitivity and central sleep apnoea in this disorder.

106 ignificantly reduced the severity of central sleep apnoea, including improvements in sleep metrics, a

107 hyroidism (IRR 7.22, 6.62-7.88), obstructive sleep apnoea (IRR 4.45, 3.72-5.31), and haematological m

108 Obstructive sleep apnoea is a common disease that is now more widely

109 Obstructive sleep apnoea is a disease of increasing importance becau

110 There is convincing evidence to believe that sleep apnoea is a modifiable risk factor for stroke; how

111 Central sleep apnoea is a serious breathing disorder associated

112 Obstructive sleep apnoea is an increasingly common disorder of repea

113 Obstructive sleep apnoea is associated with raised blood pressure.

114 decades evidence suggests that treatment for sleep apnoea is feasible during the acute phase of strok

115 A co-morbidity of sleep apnoea is hypertension associated with elevated sy

116 r control and thus could explain why central sleep apnoea is less frequent in REM sleep.

117 e base for the treatment of mild obstructive sleep apnoea is limited and definitions of disease sever

118 t decrease over time, but moderate to severe sleep apnoea is nevertheless present in up to a third of

119 ronic intermittent hypoxia (CIH, a model for sleep apnoea) is a major risk factor for several cardiov

120 primary sleep disorders such as obstructive sleep apnoea may worsen epilepsy and treatment of these

121 In patients with most severe sleep apnoea, nCPAP reduces blood pressure, providing si

122 oventilation syndrome and severe obstructive sleep apnoea, non-invasive ventilation and continuous po

123 h of more than 4% SaO2 caused by obstructive sleep apnoea on overnight sleep study, were randomly ass

124 Sleep apnoea, one of the most common chronic diseases, i

125 revalent sleep disorders, namely obstructive sleep apnoea (OSA) (BPAD 50.8.0% vs RDD 29.3%, P = 0.006

126 Obstructive sleep apnoea (OSA) and type 2 diabetes frequently co-exi

127 roup of elderly individuals with obstructive sleep apnoea (OSA) for comparison (n = 3, age 68 +/- 1 y

128 ay pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in patients with cardiovascular disea

129 Obstructive sleep apnoea (OSA) is a heterogeneous and complex diseas

130 Obstructive Sleep Apnoea (OSA) is associated with the development of

131 Obstructive sleep apnoea (OSA) is characterised by intermittent hypo

132 on of oral appliance therapy for obstructive sleep apnoea (OSA) is that therapeutic responses remain

133 ther PA and vLTF are enhanced in obstructive sleep apnoea (OSA) participants compared to matched heal

134 one of the main contributors to obstructive sleep apnoea (OSA) pathogenesis.

135 *Some patients with obstructive sleep apnoea (OSA) respond well to oral appliance therap

136 re (CPAP) for moderate to severe obstructive sleep apnoea (OSA) syndrome have been established in mid

137 Obstructive sleep apnoea (OSA), characterized by recurrent periods o

138 od O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhibit a heighte

139 od O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhibit a heighte

140 ation (SF), a primary feature of obstructive sleep apnoea (OSA), impairs hippocampal long-term potent

141 a is a hallmark manifestation of obstructive sleep apnoea (OSA), which is a widespread respiratory di

142 Obstructive sleep apnoea (OSA), which is characterized by periodic i

143 loop gain (LG) in patients with obstructive sleep apnoea (OSA), yet its effects on the other traits

144 eness in people with and without obstructive sleep apnoea (OSA).

145 return to sleep in patients with obstructive sleep apnoea (OSA).

146 nt brief hypoxic episodes during obstructive sleep apnoea (OSA).

147 a risk factor for development of obstructive sleep apnoea (OSA).

148 patients with SS and those with obstructive sleep apnoea (OSA).

149 a relatively high prevalence of obstructive sleep apnoea (OSA).

150 a relatively high prevalence of obstructive sleep apnoea (OSA).

151 t that acetazolamide may improve obstructive sleep apnoea (OSA).However, how acetazolamide affects th

152 ysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporosis and venous thromboembolism.

153 ngeal obstruction determine the phenotype of sleep apnoea patients who benefit maximally from oral ap

154 creased risk for hypertension in obstructive sleep apnoea patients.

155 who demonstrated spontaneous apnoeas during sleep, apnoea per se did not alter burst latency relativ

156 rate progression of, obstructive and central sleep apnoea, possibly through the development of periph

157 Countries without obstructive sleep apnoea prevalence data were matched to a similar c

158 rm 36 mental component summary (MCS) and the sleep apnoea quality-of-life index symptoms domain (sym)

159 Our aim was to see whether nCPAP for sleep apnoea reduces blood pressure compared with the mo

160 ure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and improves hypertensi

161 sleepiness, circadian disorders, obstructive sleep apnoea, restless legs syndrome, and rapid eye move

162 The increased awareness of obstructive sleep apnoea's (OSA) links to Alzheimer's disease and ma

163 Nevertheless, sleep apnoea still remains underdiagnosed and untreated

164 lysomnography showed features of obstructive sleep apnoea, stridor, and abnormal sleep architecture (

165 sleep apnoea, and the temporal evolution of sleep apnoea subtypes following stroke remain to be clar

166 are a unifying mechanism that links central sleep apnoea, sympathoexcitation and heart failure in in

167 ) is a unifying mechanism that links central sleep apnoea, sympathoexcitation and heart failure in in

168 ortant in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

169 ortant in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

170 ntribution of genetic factors to obstructive sleep apnoea syndrome (OSAS) has led to a better underst

171 Repetitive hypoxia seen in obstructive sleep apnoea syndrome (OSAS) may affect bone metabolism

172 seven healthy humans and three patients with sleep apnoea syndrome during NREM sleep.

173 s a consequence of sleep disorders including sleep apnoea syndrome, circadian disorders, central hype

174 onalcoholic fatty liver disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontit

175 important in the pathogenesis of obstructive sleep apnoea syndrome.

176 efit was larger in patients with more severe sleep apnoea than those who had less severe apnoea, but

177 past two decades indicates that obstructive sleep apnoea, through the effects of intermittent hypoxa

178 the detection and prediction of post-stroke sleep apnoea, uncertainty as to the optimal timing for i

179 omnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms,

180 233 had mild obstructive sleep apnoea using AASM 2012 criteria and were included

181 usitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesity, dysfuncti

182 he pathogenesis and treatment of obstructive sleep apnoea, we have developed a novel application of m

183 Reliable prevalence data for obstructive sleep apnoea were available for 16 countries, from 17 st

184 Many patients with stroke have concomitant sleep apnoea, which can affect recovery potential.

185 upon such mechanisms (as in the patient with sleep apnoea) will be prone to collapse during sleep.

186 (SERVE-HF) showed that treatment of central sleep apnoea with adaptive servoventilation in patients

187 cent insights and discoveries in obstructive sleep apnoea, with a focus on diagnostics and therapeuti

188 y to report global prevalence of obstructive sleep apnoea; with almost 1 billion people affected, and